The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up

Erica Huelsmann; Israel Zighelboim; Amina Ahmed; Summer Dewdney

doi:10.1016/j.gore.2017.02.005

The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up

Gynecol Oncol Rep. 2017 Feb 16:20:47-50. doi: 10.1016/j.gore.2017.02.005. eCollection 2017 May.

Authors

Erica Huelsmann¹, Israel Zighelboim², Amina Ahmed³, Summer Dewdney³

Affiliations

¹ Department of Obstetrics and Gynecology, MedStar Washington Hospital Center/MedStar Georgetown University Hospital, United States.
² Department of Gynecologic Oncology, St. Luke's Cancer Care Associates, Temple University School of Medicine, United States.
³ Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Rush University Medical Center, United States.

Abstract

•NACT use among SGO members for ovarian cancer is explored given recent trials.•Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.•Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.•Very high optimal cytoreduction rates are reported from SGO members.•Despite recent studies, SGO members don't regularly treat patients with NACT/ID.